Trials / Conditions / Recurrent Malignant Uterine Corpus Neoplasm
Recurrent Malignant Uterine Corpus Neoplasm
5 registered clinical trials studyying Recurrent Malignant Uterine Corpus Neoplasm.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer NCT03348631 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT01935934 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carbopla NCT00977574 | National Cancer Institute (NCI) | Phase 2 |